ArticleTargeted oncology2026

Indirect Comparison of the Efficacy of Pembrolizumab Versus Nivolumab as Adjuvant Options for Stage IIB/IIC Melanoma.

Dimitrios A Andreikos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.